191 related articles for article (PubMed ID: 29126924)
1. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin.
Azimi A; Majidinia M; Shafiei-Irannejad V; Jahanban-Esfahlan R; Ahmadi Y; Karimian A; Mir SM; Karami H; Yousefi B
Gene; 2018 Feb; 642():249-255. PubMed ID: 29126924
[TBL] [Abstract][Full Text] [Related]
2. Effect of siRNA-mediated silencing of p53R2 gene on sensitivity of T-ALL cellsto Daunorubicin.
Kiani Ghalesardi O; Zaker F; Ghotaslou A; Boustani H; Rezvani MR; Kiani J; Shahidi M
Gene; 2023 Sep; 880():147622. PubMed ID: 37419428
[TBL] [Abstract][Full Text] [Related]
3. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization of HepG2 cells by suppression of NF-κB/p65 gene transcription with specific-siRNA.
Shi Y; Wang SY; Yao M; Sai WL; Wu W; Yang JL; Cai Y; Zheng WJ; Yao DF
World J Gastroenterol; 2015 Dec; 21(45):12814-21. PubMed ID: 26668505
[TBL] [Abstract][Full Text] [Related]
5. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma.
Byun DS; Chae KS; Ryu BK; Lee MG; Chi SG
Int J Cancer; 2002 Apr; 98(5):718-23. PubMed ID: 11920641
[TBL] [Abstract][Full Text] [Related]
6. p53R2 is a prognostic factor of melanoma and regulates proliferation and chemosensitivity of melanoma cells.
Matsushita S; Ikeda R; Fukushige T; Tajitsu Y; Gunshin K; Okumura H; Ushiyama M; Akiyama S; Kawai K; Takeda Y; Yamada K; Kanekura T
J Dermatol Sci; 2012 Oct; 68(1):19-24. PubMed ID: 22902076
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis.
Yoshida T; Haga S; Numata Y; Yamashita K; Mikami T; Ogawa T; Ohkusa T; Okayasu I
Int J Cancer; 2006 Mar; 118(6):1395-403. PubMed ID: 16206288
[TBL] [Abstract][Full Text] [Related]
8. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells.
Devlin HL; Mack PC; Burich RA; Gumerlock PH; Kung HJ; Mudryj M; deVere White RW
Mol Cancer Res; 2008 May; 6(5):808-18. PubMed ID: 18505925
[TBL] [Abstract][Full Text] [Related]
9. Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma.
Yokomakura N; Natsugoe S; Okumura H; Ikeda R; Uchikado Y; Mataki Y; Takatori H; Matsumoto M; Owaki T; Ishigami S; Aikou T
Oncol Rep; 2007 Sep; 18(3):561-7. PubMed ID: 17671702
[TBL] [Abstract][Full Text] [Related]
10. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
11. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
12. E2F1 regulates p53R2 gene expression in p53-deficient cells.
Qi JJ; Liu L; Cao JX; An GS; Li SY; Li G; Jia HT; Ni JH
Mol Cell Biochem; 2015 Jan; 399(1-2):179-88. PubMed ID: 25312903
[TBL] [Abstract][Full Text] [Related]
13. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.
Zhang K; Wu J; Wu X; Wang X; Wang Y; Zhou N; Kuo ML; Liu X; Zhou B; Chang L; Ann D; Yen Y
Mol Cancer Ther; 2011 Feb; 10(2):269-78. PubMed ID: 21216934
[TBL] [Abstract][Full Text] [Related]
14. siRNA-mediated silencing of Nanog reduces stemness properties and increases the sensitivity of HepG2 cells to cisplatin.
Alemohammad H; Motafakkerazad R; Asadzadeh Z; Farsad N; Hemmat N; Najafzadeh B; Vasefifar P; Baradaran B
Gene; 2022 May; 821():146333. PubMed ID: 35182674
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells.
Ragheb MA; Soliman MH; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
Anticancer Agents Med Chem; 2021; 21(2):237-245. PubMed ID: 32357822
[TBL] [Abstract][Full Text] [Related]
16. Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
Li Y; Farmer RW; Yang Y; Martin RC
BMC Cancer; 2016 Mar; 16():228. PubMed ID: 26984381
[TBL] [Abstract][Full Text] [Related]
17. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
19. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
20. [Small interfering RNA targeting STAT3 enhances antitumor activity of doxorubicin].
Wang TX; Wang YY; Zhang ZQ
Yao Xue Xue Bao; 2013 Jan; 48(1):52-8. PubMed ID: 23600141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
